Recent Updates — AZN
AstraZeneca announced a $2 billion equity investment in Summit Therapeutics to accelerate the development of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody. AstraZeneca will purchase approximately 109,000 shares of preferred stock convertible into common stock at a 1:1,000 ratio, resulting in rights equivalent to roughly 12.0% of Summit's outstanding common stock (10.6% fully diluted). The transaction includes a clinical collaboration to evaluate sonesitatug vedotin with ivonescimab in gastrointestinal cancers and an MOU for broader combination trials. Closing is anticipated within one week of the September 29, 2026 announcement. AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines.
AstraZeneca received European Commission approval for Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) as a maintenance treatment for asthma in patients aged 12 and older. This marks the first triple-combination therapy approved in the EU for this indication, regardless of exacerbation history. The approval follows positive opinions from the EMA's CHMP based on Phase III KALOS and LOGOS trials involving approximately 4,300 patients, which demonstrated statistically significant improvements in lung function and reductions in severe asthma exacerbations compared to dual ICS/LABA therapies. Trixeo is marketed as Breztri Aerosphere in the US, China, and Japan for both asthma and COPD treatment. AstraZeneca PLC operates in the global biopharmaceutical industry, focusing on the discovery, development, and commercialization of prescription medicines.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval in the EU for Klygefa (gefurulimab), an add-on treatment for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis. The positive opinion is based on the PREVAIL Phase III trial, which demonstrated a statistically significant improvement in Myasthenia Gravis Activities of Daily Living scores at week 26 compared to placebo (treatment difference: -1.6). If approved, Klygefa will be the first and only dual-binding nanobody C5 inhibitor for this indication in the EU, offering once-weekly subcutaneous self-administration. AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialisation of prescription medicines.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Enhertu as an adjuvant treatment for HER2-positive early breast cancer with residual disease. This recommendation is based on the DESTINY-Breast05 Phase III trial, which demonstrated that Enhertu reduced the risk of invasive disease recurrence or death by 53% compared to trastuzumab emtansine (T-DM1). At three years, 92.4% of patients in the Enhertu arm were alive and free of invasive disease versus 83.7% for T-DM1. AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines.